Abstract BCR-ABL1 kinase domain (KD) mutation status is considered to be an important
element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do …

In chronic myeloid leukemia (CML) patients, tyrosine kinase inhibitors (TKIs) may select for
drug-resistant BCR-ABL1 kinase domain (KD) mutants. Although Sanger sequencing (SS) is …

Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …

Background Kinase domain mutations in BCR-ABL1 are associated with resistance to
tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Next-generation …

The introduction of tyrosine kinase inhibitors (TKIs), starting with imatinib and followed by
second and third generation TKIs, has significantly changed the clinical management of …

Purpose Here, we studied whether amplicon next-generation deep sequencing (NGS) could
improve the detection of emerging BCR-ABL1 kinase domain mutations in chronic phase …

Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of
chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are …

Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …

Despite durable responses to imatinib in chronic myeloid leukaemia (CML), mutations in Bcr‐
Abl kinase domain (KD) are known to induce imatinib resistance and cause poor clinical …

Mutations in BCR-ABL kinase domain are associated with resistance to tyrosine kinase
inhibitors in some patients with chronic myeloid leukemia. Therefore, mutation detection …